Sanofi Appeal Puts Hospira's Generic Eloxatin On Hold
Hospira Inc.'s efforts to tap into the $1.4 billion annual U.S. market for Sanofi-Aventis' cancer treatment Eloxatin have hit a snag now that the U.S. Food and Drug Administration has suspended...To view the full article, register now.
Already a subscriber? Click here to view full article